NCT03816345 2026-04-13Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVONational Cancer Institute (NCI)Phase 1 Recruiting300 enrolled